Sevelamer/Sodium Edetate 1463 excreted by the kidneys. It may be used as a diagnostic is not less than 9.5% and not more than 13.0%, all calculated on supplement should not be given simultaneously with test for lead poisoning but measurement of blood-lead the dried basis. The calcium binding capacity, calculated on the sodium cellulose phosphate. dried basis, is not less than 1.8 mmol per g. concentrations is generally preferred. Sodium cellulose phosphate has also been used for the Sodium calcium edetate is also a chelator of other Adverse Effects and Precautions investigation of calcium absorption. heavy-metal polyvalent ions, including chromium. A Diarrhoea and other gastrointestinal disturbances have Preparations cream containing sodium calcium edetate 10% has been reported. USP 31: Cellulose Sodium Phosphate for Oral Suspension. been used in the treatment of chrome ulcers and skin Sodium cellulose phosphate should not be given to pa- Proprietary Preparations (details are given in Part 3) sensitivity reactions due to contact with heavy metals. tients with primary or secondary hyperparathyroidism, Spain: Anacalcit; USA: Calcibind. Sodium calcium edetate is also used as a pharmaceuti- hypomagnesaemia, hypocalcaemia, bone disease, or cal excipient and as a food additive. enteric hyperoxaluria. It should be used cautiously in pregnant women and children, since they have high Sodium Edetate In the treatment of lead poisoning, sodium calcium calcium requirements. Sodu edetynian. edetate may be given by intramuscular injection or by Patients should be monitored for electrolyte distur- intravenous infusion. The intramuscular route may be Эдетат Натрия bances. Uptake of sodium and phosphate may increase CAS — 17421-79-3 (monosodium edetate). preferred in patients with lead encephalopathy and in- and sodium cellulose phosphate should not be given to ATC — S01XA05. creased intracranial pressure in whom excess fluids patients with renal failure or conditions requiring a re- ATC Vet — QS01XA05. must be avoided, and also in children, who have an in- stricted sodium intake such as heart failure. Theoreti- NOTE. The name sodium edetate has been used in the literature for creased risk of incipient encephalopathy. Sodium cal- cally, long-term treatment could result in calcium defi- various sodium salts of edetic acid. Do not confuse with sodium cium edetate may initially aggravate the symptoms of ciency; regular monitoring of calcium and parathyroid calcium edetate (p.1462) or etomidate (p.1783); see also Inap- propriate Administration, below. lead toxicity due to mobilisation of stored lead and it hormone has therefore been recommended. Sodium has often been given with dimercaprol (p.1444) in pa- cellulose phosphate is not a totally selective exchange tients who are symptomatic; the first dose of dimerc- Disodium Edetate (BAN) resin and the intestinal absorption of other dietary cati- Dinatrii edetas; Dinatrii Edetas Dihydricus; Dinatrio edetatas; Di- aprol should preferably be given at least 4 hours before ons may be reduced; magnesium deficiency has been the sodium calcium edetate. natriumedetaatti; Dinatriumedetat; Disodium Edathamil; Diso- reported but may be corrected by dosage reduction or dium EDTA; Disodium Tetracemate; Disodu edetynian; Edetan For intravenous infusion, 1 g of sodium calcium ede- oral magnesium supplements. Urinary excretion of disodný dihydrát; Édétate disodique; Edetate Disodium; Edetato tate should be diluted with 250 to 500 mL of glucose oxalate may increase and dietary restriction of oxalate disódico; Edetynian disodu; Natrii Edetas; Nátrium-edetát; Sodi- 5% or sodium chloride 0.9%; a concentration of 3% intake may be necessary. um Versenate. Disodium dihydrogen ethylenediaminetetra-ace- tate dihydrate . should not be exceeded. The infusion should be given ◊ Potential complications of long-term sodium cellulose phos- C10H14N2Na2O8,2H2O = 372.2. over a period of at least 1 hour. In the UK, the usual phate therapy include secondary hyperparathyroidism and bone CAS — 139-33-3 (anhydrous disodium edetate); 6381- dose is 60 to 80 mg/kg daily given in two divided dos- disease; deficiency of magnesium, copper, zinc, and iron; and 92-6 (disodium edetate dihydrate). es. In the USA, a dose of 1000 mg/m2 daily is suggest- hyperoxaluria. A study in 18 patients1 with absorptive hypercal- ATC — S01XA05. ciuria and recurrent renal stones indicated that these complica- ATC Vet — QS01XA05. ed for asymptomatic adults and children; a daily dose tions could largely be avoided if use was confined to those with of 1500 mg/m2 may be used in patients with sympto- Pharmacopoeias. In Eur. (see p.vii), Int., Jpn, and US. absorptive hypercalciuria (hypercalciuria, intestinal hyperab- Ph. Eur. 6.2 (Disodium Edetate). A white or almost white, crys- matic poisoning. Treatment is given for up to 5 days, sorption of calcium, and normal or suppressed parathyroid func- talline powder. Soluble in water; practically insoluble in alcohol. repeated if necessary after an interval of at least 2 days. tion), if the dose was adjusted so as not to reduce intestinal calci- A 5% solution in water has a pH of 4.0 to 5.5. Protect from light. um absorption or urinary calcium subnormally (the optimal Any further treatment with sodium calcium edetate USP 31 (Edetate Disodium). A white crystalline powder. Solu- maintenance dose in most patients was 10 g daily), if oral mag- ble in water. pH of a 5% solution in water is between 4.0 and 6.0. should then not be given for at least 7 days. nesium supplements were provided, and if a moderate dietary re- Alternatively, the same daily dose of sodium calcium striction of calcium and oxalate was imposed. There was no evi- dence of zinc, copper, or iron deficiency. Trisodium Edetate edetate may be given intramuscularly in 2 to 4 divided 1. Pak CYC. Clinical pharmacology of sodium cellulose phos- Edetate Trisodium (USAN); Edetato trisódico. Trisodium hydrogen doses as a 20% solution. Intramuscular injection of so- phate. J Clin Pharmacol 1979; 19: 451–7. ethylenediaminetetra-acetate . dium calcium edetate is painful and it is recommended C10H13N2Na3O8 = 358.2. that preservative-free procaine hydrochloride should Interactions CAS — 150-38-9. be added to a concentration of 0.5 to 1.5% to minimise Sodium cellulose phosphate binds with calcium and ATC — S01XA05. pain; alternatively, lidocaine may be added to a con- other cations. Use with calcium or magnesium salts, in- ATC Vet — QS01XA05. cluding cation-donating antacids or laxatives, may re- centration of 0.5%. Te t r a s o d i u m E d e t a t e duce its efficacy. Magnesium supplements are often re- As excretion is mainly renal, an adequate urinary flow quired in patients receiving sodium cellulose Edetate Sodium (USAN). C H N Na O = 380.2. must be established and maintained during treatment. phosphate but should be given at least one hour before 10 12 2 4 8 Doses should be reduced in patients with renal impair- CAS — 64-02-8. or after any dose of the resin since the absorption of the ATC — S01XA05. ment (see below). magnesium may otherwise be impaired. ATC Vet — QS01XA05. Administration in renal impairment. The dose of sodium calcium edetate should be reduced in patients with renal impair- Uses and Administration - + ment. It has been suggested that the dose is halved and given Sodium cellulose phosphate, the sodium salt of the O Na once daily in moderate impairment, and that smaller and less fre- phosphate ester of cellulose, is a cation-exchange resin quent doses are given if renal impairment is severe. that exchanges sodium ions for calcium and other diva- O O Preparations lent cations. When given orally, it binds calcium ions N O- Na+ Na+ O- N BP 2008: Sodium Calcium Edetate Intravenous Infusion; within the stomach and intestine to form a non-absorb- USP 31: Edetate Calcium Disodium Injection. able complex which is excreted in the faeces. Theoret- O O Proprietary Preparations (details are given in Part 3) ically a 5-g dose will bind about 350 mg calcium. It is Ger.: Calcium Vitis†; Gr.: Ledclair; Irl.: Ledclair; Switz.: Chelintox†; Turk.: used in the treatment of absorptive hypercalciuria type O- Na+ Libenta; UK: Ledclair. I with recurrent formation of calcium-containing renal Multi-ingredient: Arg.: Calcium C. calculi (p.2181), usually with a moderate dietary calci- Incompatibility. See under Edetic Acid, p.1445. um restriction. Sodium cellulose phosphate is also used in the treatment of hypercalcaemia associated with os- Adverse Effects and Treatment teopetrosis, sarcoidosis, and vitamin D intoxication, In common with other edetates (see Sodium Calcium Sodium Cellulose Phosphate and in idiopathic hypercalcaemia of infancy, although Edetate, p.1462), sodium edetate may cause gastroin- other more effective agents are usually used (see Vita- testinal effects such as nausea, vomiting, and diar- Cellulose Sodium Phosphate (USAN); Celulosa, fosfato sódico de. min D-mediated Hypercalcaemia, p.1668). rhoea. Pain at the site of injection and thrombophlebitis CAS — 9038-41-9; 68444-58-6. The usual initial dose is 15 g daily by mouth in 3 divid- may also occur. Other adverse effects include fever, ATC — V03AG01. ed doses with meals reducing to 10 g daily for mainte- headache, skin rashes, hypotension, and hyperuricae- ATC Vet — QV03AG01. nance. A suggested dose for children is 10 g daily (but mia; nephrotoxicity has also been reported, particularly following overdosage. Pharmacopoeias. In US. see Adverse Effects and Precautions, above). The pow- USP 31 (Cellulose Sodium Phosphate). It is prepared by the der may be taken dispersed in water or sprinkled onto Hypocalcaemia can occur, particularly if sodium ede- phosphorylation of alpha cellulose. A free-flowing, cream-col- food. Oral magnesium supplements equivalent to tate is infused too rapidly or in too concentrated a solu- oured, odourless, powder. Insoluble in water, in dilute acids, and about 60 or 90 mg (about 2.4 or 3.6 mmol) of elemen- tion and tetany, convulsions, respiratory arrest, and car- in most organic solvents.